# Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

Study · id `cardio:ct-nct04433572` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04433572](<https://clinicaltrials.gov/study/NCT04433572>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04433572

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT04433572. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-30 (actual); primary completion 2028-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT04433572, source copy `cardio:ctgov-nct04433572-2025-08-05`, retrieved 2026-10-31)
- Started: 2025-07-30 (actual) (ClinicalTrials.gov record NCT04433572, source copy `cardio:ctgov-nct04433572-2025-08-05`, retrieved 2026-10-31)
- Primary completion: 2028-02-01 (anticipated) (ClinicalTrials.gov record NCT04433572, source copy `cardio:ctgov-nct04433572-2025-08-05`, retrieved 2026-10-31)
- Completion: 2032-08-01 (anticipated) (ClinicalTrials.gov record NCT04433572, source copy `cardio:ctgov-nct04433572-2025-08-05`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04433572, source copy `cardio:ctgov-nct04433572-2025-08-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04433572-2025-08-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
- Acronym: TANGO-3
- Condition: Peripheral Artery Disease
- Condition: Critical Limb Ischemia
- Intervention (Drug): Temsirolimus
- Intervention (Drug): Saline placebo
- Lead sponsor: Mercator MedSystems, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 67b9c50814b0374c41501f0b9b6f02015bd571c43cb597711b74f29e781ce272
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
